Radioligand Therapy 177Lu-PSMA-617 in Patients With Progressive PSMA-positive mCRPC

Evan Y. Yu, MD, reviews the use of LuPSMA radioligand therapy and the role of precision medicine in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer.

EP. 1: Role of Precision Medicine in PSMA-Positive mCRPC

August 20th 2021

Evan Y. Yu, MD, shares insight on the rationale for precision medicine in patients with progressive PSMA-positive metastatic castration resistant prostate cancer (mCRPC) who have been previously treated with androgen axis inhibitor drugs and taxane.

EP. 2: PSMA-Positive mCRPC: Phase 3 VISION Trial

August 20th 2021

Dr Evan Y. Yu reviews the use of 177Lu-PSMA-617 therapy in patients with progressive PSMA-positive mCRPC as seen in the phase 3 VISION trial.

EP. 3: Patient Response to LuPSMA Therapy in mCRPC

August 20th 2021

An expert in prostate cancer comments on patient response to 177Lu-PSMA-617 therapy, particularly for patients with mCRPC who have liver metastases.

EP. 4: Phase 2 TheraP Trial in PSMA-Positive mCRPC

August 20th 2021

Evan Y. Yu, MD, reviews the phase 2 TheraP trial evaluating PSA response in patients with PSMA-positive mCRPC who received LuPSMA therapy vs cabazitaxel.

EP. 5: Sequencing of LuPSMA Therapy in PSMA-Positive mCRPC

August 20th 2021

Dr Evan Y. Yu shares sequencing strategies for LuPSMA radioligand therapy in patients with PSMA-positive mCRPC.